Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marc van Baardewijk"'
Autor:
Anthony H. Barnett, Marc van Baardewijk, Martin Knapp, Gilbert L'Italien, Jean-Yves Loze, Helen L Millar
Publikováno v:
European Archives of Psychiatry and Clinical Neuroscience. 259:239-247
Patients with schizophrenia experience elevated rates of morbidity and mortality, largely due to an increased incidence of cardiovascular disease and diabetes. There is increasing concern that some atypical antipsychotic therapies are associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::177d373b905a493347325adb9d492106
https://doi.org/10.1007/s00406-008-0863-2
https://doi.org/10.1007/s00406-008-0863-2
Autor:
Marc van Baardewijk, Kawitha Vardeva, Andrew Davies, Jean-Yves Loze, K. Sennfält, Gilbert L'Italien
Publikováno v:
Current Medical Research and Opinion. 24:3275-3285
To evaluate the cost-effectiveness of atypical antipsychotic treatment sequences for the management of stable schizophrenia in the UK.A Markov model was developed to assess the cost per quality-adjusted life year (QALY) gained from 12 alternative tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a1e18b2804235ba8c7c7836f74e5168
https://doi.org/10.1185/03007990802507547
https://doi.org/10.1185/03007990802507547
Autor:
Marc van Baardewijk, Srividya Kotapati, Jeroen P. Jansen, Pascale Dequen, Paul Lorigan, Mario Ouwens
Objective. To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients. Methods. A systematic literature search was performed to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b933b51592d2f7003714044364fee3a3
https://europepmc.org/articles/PMC3500357/
https://europepmc.org/articles/PMC3500357/
Publikováno v:
The Annals of pharmacotherapy. 39(11)
BACKGROUND Duloxetine has joined venlafaxine on the antidepressant market as a second serotonin–norepinephrine reuptake inhibitor. No previous studies have directly compared these drugs. OBJECTIVE To compare indirectly the efficacy and safety of ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68dc01315139db419db954d412b0090e
https://pubmed.ncbi.nlm.nih.gov/16189284
https://pubmed.ncbi.nlm.nih.gov/16189284
Autor:
Juan Luis Steegmann, Miranda Pans, David Marin, Marc van Baardewijk, Gregor Verhoef, Aloysius Ho, Gert J. Ossenkoppele, Mats Björeman, M. Lurdes Guerra, Mauricette Michallet, Ernst Schloegl, Andrzej Hellmann, Kajetana Foryciarz, Enrica Morra, Ave Mori, Kazimierz Kuliczkowski, Antonella Gozzini, Dietger Niederwieser
Publikováno v:
Blood. 118:1689-1689
Abstract 1689 Background: Approximately half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) fail imatinib treatment, both in interventional (Deininger et al., Blood 2009 114: abstract 1126) and observational trials (Michallet et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1f42553a5dfff7f19d41c8bb38d5652
https://doi.org/10.1182/blood.v118.21.1689.1689
https://doi.org/10.1182/blood.v118.21.1689.1689
Autor:
Andrew Davies, Kawitha Vardeva, Jean-Yves Loze, Gilbert J. L'Italien, Karin Sennfalt, Marc van Baardewijk
Publikováno v:
Current Medical Research & Opinion; Nov2008, Vol. 24 Issue 11, p3275-3285, 11p